Diagnosis and pharmacological management of Parkinson's disease: Summary of SIGN guidelines

BMJ (Online)

Volumn 340, Issue 7739, 2010, Pages 206-

  Grosset, D G ^a   Macphee, G J A ^a   Nairn, M ^b  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b Scottish Intercollegiate Guidelines Network   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DESIPRAMINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DAYTIME SOMNOLENCE; DEMENTIA; DEPRESSION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG WITHDRAWAL; EXPERIENCE; GROUPS BY AGE; HUMAN; LOW DRUG DOSE; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

FAMILY PRACTICE; GENETIC TESTING; HUMANS; MOOD DISORDERS; NOOTROPIC AGENTS; PARKINSON DISEASE; PRACTICE GUIDELINES AS TOPIC; PSYCHOMOTOR DISORDERS;

EID: 76249106652     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b5614     Document Type: Review

References (22)

1. General Register Office for Scotland. Projected population of Scotland (2008 based). 2009. www.groscotland. gov.uk/files2/stats/projected-population- of-scotland-2008-based/projected-populationof-scotland-2008-based-publication/ projected-population-of-scotland-2008-based.pdf
2. Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson's disease. Edinburgh: SIGN, 2010. (SIGN publication No 113) www.sign.ac.uk/guidelines/fulltext /113/index.html
3. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.[Abstract/Free Full Text]
4. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916-23.[CrossRef][Web of Science] [Medline]
5. Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Petracca G, et al. A validation study of depressive syndromes in Parkinson's disease. Mov Disord 2008;23:538-46.[CrossRef][Web of Science] [Medline]
6. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-92. [CrossRef][Web of Science][Medline]
7. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.[Free Full Text] .
8. Montgomery SA, Asberg M. A new depression scale, designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.[Abstract/Free Full Text]
9. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.[Abstract/Free Full Text]
10. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebocontrolled study. Mov Disord 2008;23:850-7.[CrossRef][Web of Science][Medline]
11. Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005;20:1161-9.[CrossRef][Web of Science][Medline]
12. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58.[CrossRef][Web of Science] [Medline]
13. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999;14:922-7.[CrossRef][Web of Science][Medline]
14. Gjerstad M. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 2006;67:853-8.[Abstract/Free Full Text]
15. Tan EK, Lum SY, Fook-Chong SM, Teoh ML, Yih Y, Tan L, et al. Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls. Neurology 2002;58:465-8. [Abstract/Free Full Text]
16. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20:1255-63. [CrossRef][Web of Science][Medline]
17. Leroi I, Collins D, Marsh L. Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: A review. J Neurol Sci 2006;248:104-14.[CrossRef][Web of Science][Medline]
18. Maidment ID, Fox C, Boustani M. A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia. Acta Psychiatr Scand 2005;111:403-9.[CrossRef][Web of Science][Medline]
19. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:164-71.[Abstract]
20. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002;73:529-34.[Abstract/Free Full Text]
21. Lang AE, When and how should treatment be started in Parkinson disease? Neurology 2009;72(suppl 7):S39-43.[Abstract/Free Full Text]
22. Sellbach AN, Boyle RS, Silburn PA, Mellick GD. Review: Parkinson's disease and family history. Parkinsonism and Related Disorders 2006;12:399-409.[CrossRef][Web of Science][Medline]